Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €14.70 EUR
Change Today -0.05 / -0.34%
Volume 0.0
41L On Other Exchanges
Symbol
Exchange
Berlin
Continuous
As of 9:09 AM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

laboratorios farmaceuticos r (41L) Snapshot

Open
€14.75
Previous Close
€14.75
Day High
€14.96
Day Low
€14.61
52 Week High
03/31/15 - €16.40
52 Week Low
09/25/14 - €7.99
Market Cap
735.0M
Average Volume 10 Days
93.8
EPS TTM
--
Shares Outstanding
50.0M
EX-Date
07/2/15
P/E TM
--
Dividend
€0.17
Dividend Yield
1.15%
Current Stock Chart for LABORATORIOS FARMACEUTICOS R (41L)

Related News

No related news articles were found.

laboratorios farmaceuticos r (41L) Related Businessweek News

No Related Businessweek News Found

laboratorios farmaceuticos r (41L) Details

Laboratorios Farmaceúticos Rovi, S.A. engages in the research, development, in-licensing, manufacture, and marketing of small molecule and specialty biologic drugs in Spain and internationally. The company’s principal product is Bemiparin, a low molecular weight heparin. Its prescription products comprise Hibor to prevent thromboembolic disease; Osseor to treat osteoporosis; Hepadren for the prevention of clotting in the extracorporeal circuit; Hirobriz and Ulunar Breezhaler for the treatment of chronic obstructive pulmonary disease; Glufan for relieving symptoms of degenerative osteoarthritis (OA); and Corlentor for treating coronary artery disease and chronic heart failure. The company’s prescription products also include Exxiv for relieving the symptoms of OA, rheumatoid arthritis, ankylosing spondylitis,, and acute gouty arthritis; Calcio y Vitamina D3 ROVI to treat osteoporosis; Bertanel to treat adults active rheumatoid, juvenile idiopatic, and psoriatic arthritis; Vytorin for patients with primary hypercholesterolaemia or mixed hyperlipidaemia; Absorcol for patients with hypercholesterolaemia and phytosterolaemia; Thymanax for treating depressive episodes in adults; and Volutsa for the treatment of benign prostatic hyperplasia. In addition, it offers diagnostic products, such as SonoVue for use in ultrasound imaging; Iopamiro and Iomeron radiographic contrast media for diagnosis; and Multihance and Prohance for use in diagnostic magnetic resonance imaging. Further, the company provides OTC products comprising Perspirex to control sweating from the underarms; Enerzone, a protein product; Dentimelo to repair oral mucosal lesions and gums; ColdPack cold and hot bag for reliving pain; and Nitview Ledcomb, a product for lice and nits. Additionally, it distributes products licensed from other laboratories. The company was founded in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Inversiones Clidia, S.L.

1,109 Employees
Last Reported Date: 02/25/15
Founded in 1946

laboratorios farmaceuticos r (41L) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: €425.0K
Chairman of The Board, Chief Executive Manage...
Total Annual Compensation: €251.0K
Chief Financial Officer and Executive Directo...
Total Annual Compensation: €311.0K
Director of Corporate Development and Directo...
Total Annual Compensation: €312.0K
Compensation as of Fiscal Year 2014.

laboratorios farmaceuticos r (41L) Key Developments

Rovi Signs Distribution Agreement with Merck Sharp & Dohme SA

Rovi signed a distribution agreement with Merck Sharp & Dohme SA to market Orvatez (ezetimibe + atorvastatin) in Spain. Orvatez combines two main active ingredients, ezetimibe and atorvastatin, which act by inhibiting two sources of origin of cholesterol. Orvatez is indicated for adult patients with primary hypercholesterolemia (increased levels of cholesterol in blood) or mixed (high levels of cholesterol and triglycerides in blood) when the use of the combination product is considered adequate.

Laboratorios Farmaceuticos ROVI, S.A., Annual General Meeting, Jun 09, 2015

Laboratorios Farmaceuticos ROVI, S.A., Annual General Meeting, Jun 09, 2015., at 11:00 Central European Standard Time. Location: AC Cuzco Hotel.

Rovi Announces Earnings Results for the First Quarter of 2015

Rovi announced earnings results for the first quarter of 2015. For the quarter, the company reported a net profit of EUR 6.5 million (USD 7.2 million), 9% more than in the same period of 2014, supported by an increase in operating revenues from 5% to EUR 60.8 million. The gross operating result (EBITDA) improved by 7% and totaled EUR 9.6 million, while total sales of prescription pharmaceutical products rose 3% and amounted to EUR 35.6 million. Total revenues increased by 4% to EUR 61.1 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
41L:GR €14.70 EUR -0.05

41L Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 41L.
View Industry Companies
 

Industry Analysis

41L

Industry Average

Valuation 41L Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 22.9x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LABORATORIOS FARMACEUTICOS R, please visit www.rovi.es. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.